NFKB2 and cancer: Such hyperactivation of NF-κB signaling in cancer may be achieved by chromosomal alterations directly affecting members of the NF-κB pathway, as amplification of c-Rel on chromosome 2p14–15, chromosomal rearrangements or deletions affecting the NF-κB2 locus on chromosome 10q24, t(14;19)(q32;q13) translocation resulting in increased expression of the transcriptional coactivator of p50 or p52 homodimers Bcl-3, and loss-of-function mutations in IkBα (reviewed in [131]).